

Expert Opinion

1. Overview of the market
2. How the technology works
3. Phase I clinical studies
4. Phase IIa clinical studies
5. Phase II clinical studies
6. Safety aspects
7. Alternative technologies
8. Economical considerations
9. Conclusion
10. Expert opinion

Pulmonary insulin delivery by means of the Technosphere™ drug carrier mechanism

Andreas Pfützner[†] & Thomas Forst

[†]*Institute for Clinical Research and Development, Parcustr. 8, D-55116 Mainz, Germany*

Technosphere™/Insulin (TI) is a formulation of regular human insulin designed for efficient transport across the respiratory epithelium into the circulation. The drug carrier mechanism achieves a fast systemic insulin uptake (maximum time ~ 15 – 20 min), a fast onset of action (maximum activity ~ 25 – 30 min) and a short duration of action (~ 2 h). Bioavailability, relative to subcutaneous injection, was established to be between 30 and 50% with a linear dose–response relationship and low variability. In all published short-term studies, TI was well tolerated. Provided a reliable long-term safety profile, TI may become a suitable alternative to subcutaneous injection for prandial insulin delivery. TI offers the possibility of new treatment regimens, especially in patients with Type 2 diabetes.

Keywords: diabetes mellitus, inhalation, pulmonary insulin, Technosphere™

Expert Opin. Drug Deliv. (2005) 2(6):1097-1106

1. Overview of the market

Subcutaneous injection is today the only approved effective way for administering insulin in daily clinical routine. The beneficial effect of multiple daily injection regimens has been clearly demonstrated in landmark studies such as the Diabetes Control and Complications Trial [1], and even the United Kingdom Prevention of Diabetes Study provides evidence of the positive impact of improved glycaemic control on the prognosis of Type 2 diabetic patients, despite major design problems [2]. Patients with Type 2 diabetes commonly undervalue the role of lifestyle changes and pharmacological therapy in preventing future complications. Negative emotions and preconceptions about treatment can also discourage adherence to treatment plans. Psychological insulin resistance caused by fear and concerns about insulin and daily insulin injections can discourage many patients from starting insulin therapy, even if oral agents have failed [3,4].

As a consequence, many different routes of application have been investigated since the discovery of insulin > 80 years ago, including oral, rectal, intrascrotal, sublingual, ocular, vaginal, pulmonary, tracheal, transdermal and intranasal approaches [5]. Although some companies and research groups are seriously working on oral insulin delivery, so far only the pulmonary route of administration can be seriously considered to become a suitable alternative to subcutaneous injections. The lung, with its vast and well-perfused absorptive surface, its thin alveolar–capillary barrier, a marginal variance in the amount of mucus production and the absence of an immediate insulin degradation by the liver, has some inherent advantages for insulin administration as given in Table 1 [6–8].

Currently, several inhaled insulin formulations are being tested in Phase II – III clinical trials, as discussed in Section 7, and a variety of well-controlled studies have been published in recent years. Some of the pulmonary insulin developments use liquid insulin, whereas others administer dry powder formulations with different inhaler technologies of varying complexities to achieve the optimal particle size of 1 – 3 µm for delivery to the alveoli in the deep lung [9]. However, dry powder formulations

Ashley Publications
www.ashley-pub.com



Table 1. Advantages for pulmonary versus injectable insulin.

Parameter	Injectable insulin	Pulmonary insulin
Patient-related factors		
Psychological barriers	High	Low
Pain	Pain is dependent on the injection devices used	No pain
Acceptance for multiple applications	Low	High
Stigmatisation	Drug abuser	None
Technical parameters		
Absorption surface area	Small region in the subcutaneous tissue	Large pulmonary surface (size of a tennis court)
Pharmacokinetics	Variable and relatively slow absorption Changes in pharmacokinetics require changes in insulin chemistry	Fast absorption, lower variability similar to subcutaneous Changes in pharmacokinetics can be obtained by mechanisms modulating pulmonary absorption
Storage conditions	Unstable Cooling required (4 – 8°C) No freezing	Relatively stable Room temperature Freezing possible (only dry powder formulations)

Table 2. Differences between liquid and dry powder formulations for pulmonary insulin delivery.

Parameter	Pulmonary insulin formulations	
	Liquid	Dry powder
Bioavailability (compared with subcutaneous injections)	15 – 20%	10 – 50%*
T _{max}	40 – 50 min	15 – 60 min*
Stability	Similar to subcutaneous insulin formulations	Stable at room temperature Freezing possible
Dosing (in subcutaneous equivalents)	1 IU	3 IU
External energy (battery) requirements for deagglomeration	High	None or low
Risk for microbial growth	Substantial	Low

*Reported for different formulations.

T_{max} : Time to reach maximal effect.

seem to have some favourable advantages, such as (but not limited to) stability at room temperature, stability of particle size or low susceptibility to microbial growth [10]. Another advantage of pulmonary insulin delivery seems to be improvements in the pharmacokinetic and pharmacodynamic profiles leading to a faster onset and shorter duration of action, which improves the overall reliability and convenience for postprandial glucose control, by achieving insulin concentrations close to, or identical with, short-acting insulin analogues [11,12]. A comparison between liquid and dry powder formulations is provided in Table 2.

Today, the largest body of clinical data is published for the most advanced product Exubera® (Pfizer/Nektar), a dry powder development that was filed for approval in Europe in February 2004 and for the new drug application in the US in December 2004. All other pulmonary insulin developments will have to continue for several years before regulatory filing may be achieved. Objections and regulatory challenges to be addressed

during the regulatory development of pulmonary insulin include questions of pulmonary function impairment over long-term use as indicated by a loss in carbon monoxide diffusion capacity, and an increased immunogenicity leading to substantially higher antibody levels as compared with subcutaneous insulin injections [13]. However, recent publications and presentations at the large conferences seem to provide evidence of an acceptable safety and tolerability profile, at least for the Exubera technology [14-17]. Despite an increasing knowledge about the interaction of insulin with the lung tissue, open questions still concern the long-term impact of pulmonary insulin delivery on pulmonary function. Other unmet needs that require further investigation include insulin deposition into the respiratory tract after inhalation and also more practical issues, such as inhaler size, practicability of the inhalation procedure, and economic and reimbursement issues, as the low relative bioavailability of 10 – 20% (measured over 6 h) of most of the pulmonary developments may require a higher price of the final




Figure 1. Scheme of the Technosphere™ drug carrier mechanism.

DKP: Diketopiperazine.

end product. Some of these challenges may be met by Technosphere™/Insulin (TI), a pulmonary insulin formulation that provides the further focus of this article.

2. How the technology works

Technosphere (developed by MannKind Biopharmaceuticals; former name Pharmaceutical Discovery Corp.) is a general drug carrier technology that captures and stabilises peptides or proteins in small precipitated particles. A well-characterised small organic molecule, 3,6-*bis*(*N*-fumaryl-*N*-(*n*-butyl)amino)-2,5-diketopiperazine, self-assembles by hydrogen binding in a mild acid environment into microspheres with a mean diameter of ~ 2 – 3 μm. In the precipitation process, it traps and microencapsulates peptides and proteins, such as insulin or parathyroid hormone, that are present in the solution during self assembly. The precipitates are freeze dried and become a light powder, suitable for pulmonary delivery to the systemic circulation (Figure 1). When administered by the pulmonary route, Technosphere dissolves in the pH-neutral environment of the deep lung and facilitates the

rapid and efficient absorption of the peptide or protein into the systemic circulation. In the basic environment of plasma, the organic molecules immediately deagglomerate, and the peptide or protein is released into the plasma within seconds. The carrier molecules are not metabolised and are excreted as ammonium salts in the urine within hours of administration. A scheme of the Technosphere drug carrier mechanism is provided in Figure 1. Clinical work using Technosphere to apply parathyroid hormone, insulin, glucagon and other drugs via pulmonary and subcutaneous administration has already demonstrated the efficacy, reliability and short-term tolerability of this drug delivery system [18-22].

3. Phase I clinical studies

In the first pilot study with five healthy volunteers, TI was administered by means of a commercially available inhaler (Inhalator M®, Boehringer Ingelheim). Using the euglycaemic clamp technique, the biological efficacy and the pharmacokinetic properties of 100 IU of the new pulmonary formulation was assessed in comparison with 10 IU of subcutaneously




Figure 2. Serum insulin concentrations after application of insulin 5 IU i.v., insulin 10 IU s.c. and pulmonary Technosphere™/Insulin 100 IU in five healthy volunteers in a proof of concept euglycaemic clamp study [20]. Reprinted with permission from PFÜTZNER A, MANN AE, STEINER SS: Technosphere™/Insulin – a new approach for effective delivery of human insulin via the pulmonary route. *Diab. Technol. Ther.* (2002) 4:589-594 [21].

injected and 5 IU of intravenously injected regular human insulin (HI). TI was shown to have a very fast onset of systemic uptake (maximum time [T_{max}] 13 ± 4 min) in comparison with the subcutaneous injection (121 ± 74 min; $p < 0.001$), resembling the incline of insulin uptake observed with intravenous application (9 ± 4 min). In parallel, the pharmacodynamic profile indicated the peak biological activity after 30 min. This is considerably faster than any reported onset of action of the other actual pulmonary insulin preparations. After inhalation, insulin levels declined to baseline within 3 h. The area under the curve for this time period, however, was more than twice as high as those for intravenous and subcutaneous injections of regular HI in the context of the delivered doses (Figure 2), which requires discussion. The relative bioavailability in the first 3 h was $26 \pm 12\%$ (6 h: $16 \pm 8\%$). No adverse events were observed with any of the three single treatment doses and, in particular, no differences were seen in pulmonary function tests performed before and after the study [20].

A Phase I dose–response study evaluated the effect of three different doses (25, 50 and 100 IU) of TI in healthy volunteers, again by means of the euglycaemic clamp technique. The drug was inhaled by 12 healthy volunteers on three different study days, now using a specifically developed inhaler. A step-wise, dose-dependent increase in metabolic activity and systemic insulin uptake was observed. The bioavailability, relative to subcutaneous insulin delivery, over the first 3 h was 46, 42 and 28, respectively. The systemic insulin uptake showed a linear dose–response effect [21,23].

A pilot study, performed in five healthy volunteers, investigated the distribution pattern of TI particles in the human body. The particles were radiolabelled with ^{99}Tc by means of a passive mass-adhesion labelling technique in a nebuliser chamber, and γ -scintigraphy was applied to assess the distribution of the drug during the inhalation process. The respirable fraction of the radioactively labelled powder was determined to be 52% with an Andersen cascade impactor analysis. It could be shown by γ -camera imaging 4 min after inhalation that the TI particles were equally distributed in the whole lung with detection of 31.7% (range 20.4 – 38.8%) of the emitted dose in the left lung and 27.2% (range 22.7 – 34.4%) in the right. Of the activity, 30% was seen in the oropharynx and 10.7% was detected in the stomach. No activity could be observed in the trachea or the larger bronchi. In the same time, serum insulin levels increased quickly to reach a maximum concentration (C_{max}) value of 46 ± 21 $\mu\text{U/ml}$ within 15 min after inhalation. This study demonstrated that the amount of TI that finally reached the alveoli was equally distributed in the whole area of the two lungs. It was concluded that the use of the entire exchange surface of the lung may contribute to the fast absorption of TI into the blood. Although no direct calculation of the bioavailability could be performed in this experiment, it may be noteworthy that the amount of insulin that finally reached the deep lung is comparable with the relative bioavailability of $\sim 30\%$ within the first 6 h after inhalation, which was up to that time seen in the appropriately performed clinical experiments [24].

4. Phase IIa clinical studies

An unpredictable variability of insulin absorption and action has been observed with the subcutaneous injection of regular HI and long-acting basal insulin analogues [25]. Multiple studies have been performed with TI during the past 5 years to investigate intra-subject variability in patients with Type 2 diabetes. The variability of three repeated inhalations of TI 100 IU was assessed by euglycaemic clamp technique in 12 patients with Type 2 diabetes. In this study, the intra-individual variability in Type 2 patients was in the range of the variability observed with regular subcutaneous HI in healthy volunteers (Figure 3) [20]. The pharmacokinetic and pharmacodynamic profile that had been reported for TI in the healthy volunteers was confirmed in the Type 2 patients. The mean relative bioavailability within the first 3 h was calculated to be 50% in this study [26].

A second variability study provided a head-to-head comparison of absorption variability for subcutaneous insulin and inhaled TI in patients with Type 2 diabetes. The individual within-patient variability of the maximal serum insulin concentrations was $14.1 \pm 11.3\%$ for 48 IU of pulmonary TI (C_{max} 126.7 ± 40.5 $\mu\text{U/ml}$) compared with $16.9 \pm 9.3\%$ for 15 IU of regular HI (C_{max} 107.6 ± 57.8 $\mu\text{U/ml}$, not significant).




Figure 3. Variability of repeated inhalations of Technosphere™/Insulin 100 IU in patients with Type 2 diabetes. Reprinted with permission from PFÜTZNER A, MANN AE, STEINER SS: Technosphere™/Insulin – a new approach for effective delivery of human insulin via the pulmonary route. *Diab. Technol. Ther.* (2002) **4**:589-594 [21].

In comparison with subcutaneous injection of 10 IU of regular HI, pulmonary delivery of TI 48 IU demonstrated a lower variability for maximally achieved serum insulin concentrations and total systemic uptake. Metabolic control as measured by glucose needs was comparable for both treatment regimens [27].

A recent third study, again applying the euglycaemic clamp technique, compared 24 IU of regular subcutaneous HI with inhalation of TI 48 IU in 12 patients with Type 2 diabetes. This study confirms that TI also has a lower variability in biological insulin action as measured by the area under the curve for the glucose infusion rates (e.g., variability of the glucose infusion rate for 180 min: TI 22%; subcutaneous insulin 33%) [28].

5. Phase II clinical studies

The first 3-month randomised, parallel Phase II study was performed in 119 patients with Type 2 diabetes inadequately controlled on diet or oral agents (haemoglobin A1c [HbA1c] 6.6 – 10.0%). They received individual doses of TI or Technosphere placebo prior to each major meal. A significant improvement in HbA1c was seen in both study groups (placebo -0.31%; verum -0.72%). This effect was dependent on

the baseline HbA1c and was certainly induced in the placebo arm by the improved care for the patients throughout the study. However, HbA1c was significantly better at end point in the verum arm ($p < 0.005$ between groups at end point). Both Technosphere treatments were well tolerated. No severe hypoglycaemic event occurred in the verum group, and there was no impairment in pulmonary function or induction of antibodies [29]. Although this US Phase II study has already been completed, other Phase II and III studies with TI are currently ongoing worldwide.

TI has been shown to effectively lower postprandial blood glucose excursions. The most intriguing treatment option is emerging due to its very fast onset of action, with a rapid increase to already reach C_{max} within ~ 15 min. It has been shown that patients with Type 2 diabetes in the early stage of β -cell dysfunction experience an initial lack of the so-called first-phase insulin response. This term describes a short-acting signalling peak of insulin occurring in the plasma shortly before the start of glucose absorption in the intestine tract after food uptake. This peak physiologically mediates the shutdown of hepatic gluconeogenesis, as this production is not required while glucose is absorbed in vast amounts in the gut. The

amount of insulin secreted in the first phase equals 3 IU of intravenously injected insulin, and the peak occurs within 10 – 15 min after start of the meal. Depending on the stage of β -cell dysfunction, restoration of this peak may enable the body to regain physiological control over the postprandial glucose excursions [30,31].

In a pilot study with 12 insulin-treated patients with Type 2 diabetes, the authors have been able to demonstrate that intravenous restoration of first-phase insulin response (with 3 IU) prior to a standardised meal had no effect on postprandial glucose excursions in seven patients, whereas a major improvement was seen in five of the patients. The same clinical efficacy, however, could be achieved by applying TI 12 IU [32]. In a subsequent laboratory investigation, two patient groups were distinct with regard to their β -cell dysfunction status as measured by fasting intact proinsulin concentrations, a recently described highly specific indirect indicator of advanced insulin resistance [33,34].

Using TI to mimic the early-phase response, the relationship between time, insulin concentration and glucose elimination rate (GIR) in a group of 12 subjects with Type 2 diabetes was investigated during a euglycaemic insulin clamp in a second experiment. Each subject received insulin 24 IU s.c. or TI 48 U on separate study days in a crossover design. Glucose disposal rates were reflected by the GIR required to maintain a target blood glucose of 120 mg/dl during the 540-min study period. A 48-U dose of TI provided a mean C_{\max} of 114.8 ± 44.1 mU/l with a median T_{\max} of +15 min, compared with a C_{\max} of 63 ± 10.1 mU/l and T_{\max} of +150 min after insulin 24 IU s.c. TI reached maximal GIR values of 3.33 ± 1.35 mg/kg/min at +45 min, whereas the subcutaneous dose was related to a rate of only 1.58 ± 1.03 mg/kg/min by that time. Moreover, the GIR for the subcutaneous insulin continued to climb to reach its peak of 3.38 ± 1.45 mg/kg/min at +255 min [35].

Both studies support the efficacy of TI in a treatment approach that is somewhat distinct from the current therapy philosophies, which may have consequences for further understanding and investigation of postprandial glucose control.

So far, no studies in patients with Type 1 diabetes have been published. In the ongoing clinical studies, TI can be dosed in 3 IU subcutaneous equivalent steps. It may, therefore, not be the most suitable insulin for Type 1 patients, who require dosing in smaller increments. However, it can be expected that patients with Type 1 diabetes who can adjust to the dosing possibilities will be able to use TI as a replacement for their mealtime insulin injections.

6. Safety aspects

First indications from human [29] and animal [36] experiments point to a low immunogenicity of TI. As mentioned above, initial concerns have been raised by the results with the Exubera dry powder technology, where a threefold increase in insulin antibody titres has been observed within 6 months of

treatment as compared with subcutaneous insulin injection [13]. Formation of insulin antibodies is a phenomenon that can be expected in every patient treated with insulin. Antibody titres normally increase within the first 3 – 6 months of treatment to reach a plateau and slowly decrease in the time thereafter. It is of clinical importance to investigate whether antibody titres increase beyond this initial phase, and whether these titres influence the dosing requirements for the insulin [37]. It has been shown for Exubera that the elevated antibodies do not further increase over time and that they also do not impair the efficacy of the applied doses [14–16]. Based on the Technosphere technology, it is to be expected that hydrogen binding and fast absorption may even decrease the antigen exposure from the insulin to the immune system. However, comprehensive long-term evaluations are required to further investigate this phenomenon. The same is true for the assessment of the long-term pulmonary safety and the general tolerability of the Technosphere technology. None of the animal experiments point to a risky situation for the patients in this respect. However, for the technology this is of major importance as technospheres can be applied with comparable success for pulmonary delivery of other pharmaceutically active peptides, such as parathyroid hormone [22,38,39]. TI may, therefore, represent the prototype of a whole series of future pulmonary drugs that could benefit from a peak-like pharmacokinetic profile. The question of long-term pulmonary safety can ultimately only be answered by appropriately designed long-term studies, as they will have to be performed by all companies developing pulmonary peptide delivery systems.

7. Alternative technologies

As mentioned in Section 1, several alternative pulmonary insulin technologies are currently under investigation in Phase I – III clinical studies [40]. A summary of these developments, product advantages and disadvantages, and their current regulatory status, as well as some references is provided in Table 1. It is to be expected that Pfizer/Nektar's Exubera will obtain market authorisation in Europe and the US by the end of 2005, and will be the first pulmonary insulin introduced into daily routine therapy. The Exubera technology delivers a dry powder formulation of insulin and mannose to the lung by means of a reusable mechanical inhaler, and in dose unit increments of 3 U of subcutaneous insulin equivalents [41,42]. Although it has the advantage of being 2 – 3 years ahead of the other technologies, Exubera has the largest inhaler and a low bioavailability as compared with the other pulmonary insulin technologies. However, the two companies may still use their time advantage for further improvement of the device to increase convenience and efficacy of the inhalation procedure. The next in-line technologies are the liquid formulation from Novo Nordisk/Aradigm, the dry powder drug carrier technology from Eli Lilly/Alkermes and the TI development, as listed in Table 3.

Table 3. Pulmonary insulin developments currently in advanced clinical stage (Phase II – III).

Name	Manufacturer	Phase	T _{max}	Bioavailability (relative to subcutaneous)	Formulation	(Dis)advantages of subcutaneous insulin	Ref.
Exubera®	Pfizer/Nektar	IIIb	45 – 55 min	10 – 12%	Dry powder	No injection Slightly faster PK Low bioavailability Large inhaler	[13,14]
AERx® iDMS	Novo Nordisk/ Aradigm	III	45 – 55 min	15 – 20%	Liquid	No injection Slightly faster PK Low bioavailability Heavy inhaler	[43,44]
AIR™	Eli Lilly/Alkermes	II	45 – 55 min	10%	Dry powder	No injection Comparable PK Low bioavailability Small inhaler	[45,46]
Technosphere™/Insulin	MannKind Biopharmaceuticals	II – III	15 – 20 min	26 – 50%	Dry powder	No injection Very fast PK High bioavailability Small inhaler	[20,21,23,25]
Other developments	KosPharm, Aerogen, Dura, Microdose/Elan and others	I			Dry powder or liquid		[47-49]

For reviews see [5,11,40,41].

PK: Pharmacokinetics; T_{max}: Time to reach maximal plasma insulin concentrations.

The AERx® iDMS (Novo Nordisk/Aradigm) creates aerosols from a liquid insulin formulation by means of laser-generated nozzle holes. A warm and humid air stream is created by an inhaler that is the size of a filofax. The device provides an electronic control system to guide the user to inhale with the appropriate force and timing of breath [43,44].

The AIR™ system is developed by Alkermes in collaboration with Eli Lilly. They also use a drug carrier system that produces dry powder particles of a geometric diameter of 10 – 20 µm. However, because of their low density and porous character, the particles have an aerodynamic diameter of < 5 µm. They are delivered by a mechanical and breath-activated inhaler that is the size of a small modern mobile phone [45,46].

Several other companies have also announced that they are in early clinical studies with pulmonary insulin developments. However, only limited data about their technologies are available and few clinical projects have been reported [47-49]. None of them have reached efficacy Phase II so far, but it is expected that further study results will be reported on the occasion of the next international conferences.

8. Economical considerations

Based on the low relative bioavailabilities of the different alternative pulmonary insulin developments (10 – 20%), it is to be expected that pulmonary insulin will have to be more expensive for the end user than injection of regular HI or

even insulin analogues. In this respect, Technosphere/Insulin offers the advantage of the highest absorption efficacy with ≤ 50% of the mean reported relative bioavailability within the first 3 h, which may allow a lower overall pricing. However, pulmonary insulin will have a premium price and this will be of major importance for the economic success of these products, especially in reimbursed markets in which those patient segments can be properly identified where an expected clinical benefit justifies the increased treatment expenses. This may well be those patient populations that by clinically objective measures require insulin treatment but are reluctant to start this therapy due to unspecified psychological, social and mental barriers.

9. Conclusion

For > 75 years, subcutaneous injection has been the primary means for administering insulin. A first pulmonary insulin formulation is currently under review by the regulatory agencies. Amongst the second in line developments, insulin provided to the lung by the Technosphere technology has been shown to possess protruding properties, such as a very rapid onset of action, short duration of action and the highest bioavailability (26 – 50% relative to subcutaneous administration). It may, therefore, help to improve the overall treatment situation of patients with Type 2 diabetes. The development is currently in Phase II/III and the long-term safety and tolerability profile has

so far not been established. It is, however, of utmost importance to carefully explore all aspects and implications of delivery of this technology to the lung, as it is a very attractive candidate as a drug carrier mechanism for many peptides and other molecules that currently require parenteral administration by injection or infusion.

10. Expert opinion

The development of pulmonary insulin formulations was mainly driven by the potential to overcome the psychological barrier against the use of insulin, especially in patients with Type 2 diabetes fearing the need of injections. Although the competitive developments do not show action profiles that are different to those obtained with subcutaneous injection of short-acting insulin analogues, the pharmacokinetic and

pharmacodynamic properties of TI offer several advantages for the Type 2 diabetic patient. The brief interval between administration and appearance of the maximal serum insulin levels, and the rapid onset of action may have a beneficial effect, especially in patients with early Type 2 diabetes lacking the first-phase insulin release. The shorter duration of action of TI, as compared with subcutaneously injected insulin may also better mimic the physiological insulin requirements to cover prandial glucose absorption. The ideal mealtime insulin requires a fast onset within 10 – 15 min and a duration of action of 2 – 3 h. Both requirements are fulfilled by TI. However, long-term safety and tolerability are our remaining concerns. If larger chronic studies are able to confirm the positive safety and tolerability profile that was seen for TI in short-term experiments, this technology will become a very attractive and efficient candidate for prandial insulin delivery.

Bibliography

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

- DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT): The effect of intensive insulin treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N. Engl. J. Med.* (1993) **329**:977-986.
- UNITED KINGDOM PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. *Lancet* (1998) **352**:837-853.
- SKINNER TC: Psychological barriers. *Eur. J. Endocrinol.* (2004) **151**(Suppl.2):T13-17.
- MOLLEMA ED, SNOEK FJ, ADER HJ, HEINE RJ, VAN DER PLOEG HM: Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. *J. Psychosom. Res.* (2001) **51**:665-672.
- HEINEMANN L, PFÜTZNER A, HEISE T: Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal, and pulmonary insulin delivery. *Curr. Pharm. Des.* (2001) **7**:1327-1351.
- LAUBE BL, GEORGOPOULOS A, ADAMS GK: Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. *JAMA* (1993) **269**:2106-2109.
- WIGLEY FW, LONDONO JH, WOOD SH, SHIPP JC, WALDMAN RH: Insulin across respiratory mucosae by aerosol delivery. *Diabetes* (1971) **20**:552-556.
- BYRON PR, PATTON JS: Drug delivery via the respiratory tract. *J. Aerosol. Med.* (1994) **7**:49-75.
- **Comprehensive presentation of pulmonary drug delivery.**
- BYRON PR: Prediction of residence times in regions of the human respiratory tract following aerosol inhalation. *J. Pharm. Sci.* (1986) **75**:433-438.
- PATTON JS: Deep lung delivery of therapeutic proteins. *Chemtech.* (1997) **27**:34-38.
- PATTON JS, BUKAR JG, ELTON JA: Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. *Clin. Pharmacokinet.* (2004) **43**:781-801.
- **Excellent review on pulmonary insulin, slightly biased in favour of Exubera.**
- SAKAGAMI M: Insulin disposition in the lung following oral inhalation in humans. A meta-analysis of its pharmacokinetics. *Clin. Pharmacokinet.* (2004) **43**:539-552.
- **Another excellent review of the topic.**
- QUATTRIN T, BELANGER A, BOHANNON NJ, SCHWARTZ S: EXUBERA PHASE III STUDY GROUP: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: results of a 6-month, randomized, comparative trial. *Diabetes Care* (2004) **27**:2622-2627.
- CEFALU WT, SERDAREVIC-PEHAR M; FOR THE EXUBERA PHASE III STUDY GROUP: Long-term use of Exubera in Type 2 diabetes: observations on glycemic control, pulmonary function and antibody formation. *Diabetes* (2005) **54**(Suppl.1):356-OR.
- DUMAS R, KRASNER AS, ENGLAND RD, RIESE RJ, TEETER JG FOR THE EXUBERA PHASE III STUDY GROUP: Immunologic response to Exubera in patients with Type 1 diabetes is not associated with functional evidence of airway sensitization. *Diabetes* (2005) **54**(Suppl.1):437-P.
- HEISE T, TUSEK C, STEPHAN JA *et al.*: Insulin antibodies with inhaled insulin (Exubera): no evidence for impact on postprandial glucose control. *Diabetes* (2004) **53**(Suppl.1):463-P.
- SKYLER J; FOR THE EXUBERA PHASE II STUDY GROUP: Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy. *Diabetes* (2004) **53**(Suppl. 1):486-P.
- LIAN H, STEINER SS, SOFIA RD *et al.*: A self-complementary, self-assembling microsphere system: application of intravenous delivery of the antiepileptic and neuroprotectant compound felbamate. *J. Pharm. Sci.* (2000) **89**:867-875.
- MOHNIKE K, BRETSCHNEIDER O, BRUNELLE P *et al.*: Continuous s.c. infusion with glucagon and intermittent s.c. treatment with octreotide in persistent hyperinsulinaemic hypoglycemia of infancy (PHHI). *Exp. Clin. Endocrinol. Diabetes* (2000) **108**(Suppl. 1):S127.

20. STEINER SS, PFÜTZNER A, WILSON BR, HARZER O, HEINEMANN L, RAVE K: Technosphere/Insulin – proof of concept study with a new insulin formulation for pulmonary delivery. *Exp. Clin. Endocrinol. Diabetes* (2002) **110**:17-21.
- **First clinical report about TI.**
21. PFÜTZNER A, MANN AE, STEINER SS: Technosphere™/Insulin – a new approach for effective delivery of human insulin via the pulmonary route. *Diab. Technol. Ther.* (2002) **4**:589-594.
22. PFÜTZNER A, FLACKE F, POHL R *et al.*: Technosphere/PTH(1-34) – a new approach for effective pulmonary delivery of parathyroid hormone(1-34). *Horm. Metab. Res.* (2003) **35**:319-323.
23. RAVE KM, HEISE T, PFÜTZNER A, STEINER S, HEINEMANN L: Results of a dose-response study with a new pulmonary insulin formulation and inhaler. *Diabetes* (2000) **49**(Suppl. 1):A75.
24. PFÜTZNER A, SOMMERER K, MEYER T *et al.*: Lung distribution of radiolabeled Technosphere/Insulin. *Diabetes* (2003) **52**(Suppl. 1):A107.
25. HEINEMANN L: Variability of insulin absorption and insulin action. *Diab. Technol. Ther.* (2002) **4**:673-682.
- **First comprehensive literature review on insulin variability.**
26. PFÜTZNER A, HEISE T, STEINER S, HEINEMANN L, RAVE K: Inhaled Technosphere™/Insulin shows a low variability in metabolic action in Type 2 diabetic patients. *Diabetes* (2000) **49**(Suppl. 1):A121.
27. PFÜTZNER A, POHLMANN T, HOBERG C, STEINER SS, FORST T: Variability of insulin absorption after subcutaneous and pulmonary application on patients with Type 2 diabetes. *Diabetes* (2002) **51**(Suppl. 2):A47.
28. BOSS A, HEISE T, RAVE K, CHEATHAM WW: The variability and time-action profile of inhaled Technosphere/Insulin compares favourably to that of subcutaneous human regular insulin. *Diabetes* (2005) **54**(Suppl. 1):358-OR.
29. ROSENSTOCK J, BAUGHMAN RA, RIVERA-SCHAUB T *et al.*: A randomized, double-blind, placebo controlled study of the efficacy and safety of inhaled Technosphere/Insulin in patients with Type 2 diabetes (T2D). *Diabetes* (2005) **54**(Suppl.1):357-OR.
30. BRUCE DG, CHISHOLM DJ, STORLIEN LH, KRAEGER EW: Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. *Diabetes* (1988) **37**:736-744.
- **Interesting report about the impact of intravenous restoration of first-phase insulin secretion.**
31. BRUTTOMESSO D, PIANTA A, MARI A *et al.*: Restoration of early rise in plasma insulin levels improves the glucose tolerance of Type 2 diabetic patients. *Diabetes* (1999) **48**:99-1054.
- **Insulin lispro in comparison with regular human insulin.**
32. PFÜTZNER A, HEINEMANN L, STEINER S, FORST T, HEISE T, RAVE K: Influence of small dose i.v., s.c., and pulmonary insulin treatment on prandial glucose control in patients with Type 2 diabetes. *Diabetologia* (2001) **44**(Suppl. 1):A212.
33. STEINER S, PFÜTZNER A, HEINEMANN L, LÖBIG M, HEISE T, FORST T: Intact but not total proinsulin predicts the successful imitation of first phase insulin release in patients with Type 2 diabetes. *Diabetes* (2003) **52**(Suppl.1):A544.
34. PFÜTZNER A, KUNT T, MONDOK A *et al.*: Fasting intact proinsulin is a highly specific predictor of insulin resistance in Type 2 diabetes. *Diabetes Care* (2004) **27**:682-687.
35. BOSS AH, GRANT ML, CHEATHAM WW: Mimicry of early phase insulin response in humans with rapidly available inhaled insulin accelerates postprandial glucose disposal compared to slower bioavailable insulin. *Diabetes* (2005) **54**(Suppl. 1):1373-P.
36. SIMMS JR, CARBALLO I, AUGER CR *et al.*: Assessment of immunotoxic effects on humoral and cellular immune parameters following repeated inhalation of Technosphere®/insulin in the rat. *Diabetes* (2005) **54**(Suppl.1):2078-PO.
37. FINEBERG SE, KAWABATA T, FINCO-KENT D *et al.*: Antibody response to inhaled insulin in patients with Type 1 or Type 2 diabetes. An analysis of initial Phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. *J. Clin. Endocrinol. Metab.* (2005); **90**:3287-3294.
38. PFÜTZNER A, MONDOK A, FLACKE F *et al.*: Dose response effect of pulmonary application of Technosphere/PTH(1-34). *Exp. Clin. Endocrinol. Diabetes* (2003) **111**(Suppl. 1):S25.
39. PFÜTZNER A, MONDOK A, HOBERG C *et al.*: Low variability of systemic PTH(1-34) uptake after repeated pulmonary delivery of Technosphere/PTH(1-34). *Exp. Clin. Endocrinol. Diabetes* (2003) **111**(Suppl. 1):S63.
40. HEISE T, RAVE KM, BOTT S *et al.*: Time-action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin. *Diabetes* (2000) **49**(Suppl. 1):A10.
41. OWENS DR: New horizons: alternative routes for insulin delivery. *Nature Rev. Drug Disc.* (2002) **1**:529-540.
42. SAKAGAMI M: Insulin disposition in the lung following oral inhalation in humans – a meta-analysis of its pharmacokinetics. *Clin. Pharmacokinet.* (2004) **43**:539-552.
43. BRUNNER GA, BALENT B, ELLMERE M *et al.*: Dose-response relation of liquid aerosol insulin in Type 1 diabetic patients. *Diabetologia* (2001) **44**:305-308.
44. HEISE T, SCHARLING B, BELLAIRE S *et al.*: Dose-response of pulmonary insulin with the AERx insulin diabetes management system in healthy subjects. *Diabetologia* (2001) **44**(Suppl. 2):A212.
45. RAVE K, NOSEK L, DELAPENA A *et al.*: Dose response and dose equivalency of human insulin inhalation powder (HIIP) using the Lilly/Alkermes inhaled insulin system compared to subcutaneous (sc) insulin lispro. *Diabetes* (2005) **54**(Suppl. 1):360-OR.
46. GARG S, ROSENSTOCK J, MUCHMORE D, DELAPENJA A, SUN B, SILVERMAN B: Safety and efficacy of preprandial human insulin inhalation powder (HIIP) delivered by the Lilly/Alkermes inhaled insulin system versus injectable insulin in patients with Type 1 diabetes (T1D). *Diabetes* (2005) **54**(Suppl.1):361-OR.
47. HAUSMANN M, DELLWEG S, HEINEMANN L, BUCHWALD A, HEISE T: Add-on therapy with Kos inhaled insulin dosed using a metered dose inhaler is as efficacious as add-on therapy with Lantus in poorly controlled Type 2 patients treated with sulphonylureas or metformin. *Diabetes* (2005) **54**(Suppl.1):417-P.
48. LIO Z, LIAO Y, LI Y, HU G, WENG J: Clinic pharmacokinetic study of inhaled insulin powder. *Diabetes* (2005) **54**(Suppl. 1):2072-PO.

49. PERERA AD, KAPITZA C, NOSEK L
et al. Absorption and metabolic effect of inhaled insulin: inpatient variability after inhalation via the Aerodose insulin inhaler in patients with Type 2 diabetes. *Diabetes Care* (2002) 25:2276-2281.

Affiliation

Andreas Pfützner[†] MD, PhD &

Thomas Forst MD

[†]Author for correspondence

Institute for Clinical Research and Development,

Parcusstr. 8, D-55116 Mainz, Germany

Tel: + 49 6131 5763610;

Fax: +49 6131 5763611;

E-mail: AndreasP@IKFE.de